0
Please log in or register to do it.

Emphasis on ‘breaking through limits’ by visiting Samba as his first action in the domestic field after being acquitted in the first trial

(Seoul = Larose.VIP) Reporter Jang Ha-na = Lee Jae-yong Samsung Electronics[005930] On the 16th, the Chairman visited Samsung BioLogics’ Incheon plant, which achieved record-high performance, and emphasized ‘breaking through limits’, saying, “Let’s not be satisfied with the current performance, but take on a bolder challenge.”

After visiting the Samsung SDI production corporation in Malaysia during the Lunar New Year holiday to inspect the battery business, the company visited the bio business, a new future business, a week later, continuing its active field work both at home and abroad after being acquitted in the first trial of the ‘suspicion of illegal succession of management rights’ case. .

Chairman Lee Jae-yong visits Samsung BioLogics

Chairman Lee Jae-yong visits Samsung BioLogics

On this day, Chairman Lee inspected the 5th factory site under construction and the 4th factory production line, which is currently in full operation, scheduled for completion next year. After receiving a report from Samsung BioLogics management on the technology development roadmap and mid- to long-term business strategy, he said, “We will work toward a higher goal for the future.” “Let’s move forward,” he said.

It has been 1 year and 4 months since Chairman Lee visited the Samsung BioLogics business site after attending the completion ceremony of Samsung BioLogics’ 4th factory in October 2022.

Last year, Samsung BioLogics achieved record-high performance of KRW 3.7 trillion in annual sales, KRW 1.1 trillion in operating profit, and KRW 3.5 trillion in orders on a consolidated basis.

Its subsidiary Samsung Bioepis also contributed to its highest performance by obtaining sales approval for treatments for autoimmune diseases, anticancer drugs, blood diseases, and eye diseases, exceeding KRW 1 trillion in sales within 12 years of its founding.

Chairman Lee Jae-yong inspecting the construction site of Samsung BioLogics' 5th factory

Chairman Lee Jae-yong inspecting the construction site of Samsung BioLogics’ 5th factory

Such rapid growth is said to have been based on preemptive investment decisions and bold development efforts.

After selecting bio as a new future business in 2010, Samsung established Samsung Biologics in 2011 and began its biopharmaceutical contract development and production business in earnest.

Samsung BioLogics’ annual sales, which were around 300 billion won at the time of listing in 2016, have grown 12 times in 7 years, and through aggressive investments, it has achieved the world’s No. 1 production capacity in 2022.

Currently, 14 of the top 20 global pharmaceutical companies are customers, and a 5th factory is under construction to respond to rapidly increasing customer demand. The production capacity of Plant 5, which is scheduled to start operation in April next year, is 180,000 liters.

This year, we plan to diversify our business by starting the development of antibody-drug conjugate (ADC), the next-generation anti-cancer technology.

According to the industry, the ADC market, which was worth 8 trillion won in 2022, is expected to grow significantly to 17 trillion won by 2026.

Samsung BioLogics, along with Samsung C&T and Samsung Bioepis, has created a ‘Life Science Fund’ worth 240 billion won and is making preemptive investments in future technologies. Last year, we made an equity investment in ‘Aimed Bio’, a domestic company that develops new drugs for incurable brain diseases.

Chairman Lee Jae-yong visits Samsung BioLogics Incheon business site

Chairman Lee Jae-yong visits Samsung BioLogics Incheon business site

After completing the construction of the first bio campus by completing the fourth factory, Samsung BioLogics plans to invest 7.5 trillion won by 2032 to create the second bio campus.

Accordingly, Samsung said that approximately 400 jobs are expected to be created every year, and that the effect of creating jobs for partner companies and construction workers is expected to create approximately 10,000 jobs by 2032.

The number of employees at Samsung BioLogics, which was about 100 when it was founded in 2011, has now increased to about 4,500, and more than half of all employees are in their 20s. As performance increased, the amount of corporate tax paid also doubled from 130 billion won in 2021 to 260 billion won in 2023.

hanajjang@yna.co.kr

Report to KakaoTalk okjebo 2024/02/16 16:00 Sent

Lee Hee-jun "Excited to play a murderer in his 60s... Understanding people is the charm of an actor"
Apple temporarily suspends foldable phones...

Reactions

0
0
0
0
0
0
Already reacted for this post.

Reactions

Your email address will not be published. Required fields are marked *